Details
Description
In this request, we examined utilization patterns of four biologic products indicated for treatment of ulcerative colitis in adults: adalimumab, golimumab, infliximab, and vedolizumab. Patient cohorts were assessed with an inclusion requirement of a diagnosis of ulcerative colitis and exclusion requirements of diagnoses of psoriasis, psoriatic arthritis, rheumatoid arthritis/juvenile idiopathic arthritis (RA/JIA), Crohn’s disease, ankylosing spondylitis, and hidradenitis suppurativa.
The study period includes data from January 1, 2017 to December 31, 2019. We executed this request on Merative™ MarketScan® Research Databases on September 30, 2020.